top of page

Latest News

Season 2 Premiere: Mana.bio and programmable lipid nanoparticles with CEO Yogev Debbi and RNA expert Dr Barry Ticho

May 14, 2024

Season 2 Premiere: Mana.bio and programmable lipid nanoparticles with CEO Yogev Debbi and RNA expert Dr Barry Ticho

Host Surani Fernando speaks with our CEO Yogev Debbi and fully explores our multi-layered start-up story including our origin, lab research and the challenges of launching the organization from stealth in October 2023 in the midst of the attacks on Israel.

Israeli biotech startup Mana.bio launches AI-fueled programmable drug therapy

October 11, 2023

Israeli biotech startup Mana.bio launches AI-fueled programmable drug therapy

The company is employing AI to design lipid nanoparticles (LNPs) with the goal of creating programmable drug treatments

Exclusive: Andreessen Horowitz-backed startup is using AI to design lipid nanoparticles that go beyond the liver

October 10, 2023

Exclusive: Andreessen Horowitz-backed startup is using AI to design lipid nanoparticles that go beyond the liver

One of the biggest challenges facing genetic medicines is getting them to the right part of the body. Little balls of fat called lipid nanoparticles used to carry mRNA can be injected into the arm for vaccines or infused into the blood to shuttle genetic medicines to the liver. But delivering the molecules to other cells or organs remains a challenge.

Mana.bio closes oversubscribed $19.5M seed funding

October 10, 2023

Mana.bio closes oversubscribed $19.5M seed funding

Mana.bio’s first-of-its-kind AI platform discovers and optimizes novel, customizable LNPs for tissue-specific delivery of nucleic acid-based therapeutics and vaccines, today announcing its seed funding

The Decade of RNA Delivery – Beyond the Liver

March 8, 2023

The Decade of RNA Delivery – Beyond the Liver

With the opportunity to treat spades of infectious diseases, cancers and single gene disorders, there is enormous potential in RNA therapeutics. To realize it, however, researchers will need to optimize delivery to on-target cells, minimize exposure to off-target cells and move beyond the liver.

Tech Founders, Don’t Be Afraid of Bio

January 1, 2023

Tech Founders, Don’t Be Afraid of Bio

Starting a TechBio company is a rewarding challenge. In this episode Yogev Debbi, Co-founder and CEO at Mana.bio enjoys discussing it with Omri Amirav-Drory from NFX, his co-founder from their first TechBio company Genome Compiler and now an investor at Mana.bio where we're disrupting Drug Delivery using ML/AI.

Mana.bio integrates CAS chemical substance data into its novel drug delivery AI platform

June 21, 2022

Mana.bio integrates CAS chemical substance data into its novel drug delivery AI platform

An agreement to embed chemical substance data from the CAS Content CollectionTM directly into the Mana.bio AI data acquisition workflow via an application programmable interface (API). This collaboration will enrich Mana.bio’s proprietary database to fuel its AI engine, with an expected 70% reduction in resources allocated to molecular data acquisition and preparation.

bottom of page